Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1856 • ACR Convergence 2024
Distinct Proliferative and Special Properties of Peripheral Helper T Cells in RA Synovium
Yuki Masuo¹, Akinori Murakami¹, Rinko Akamine¹, Osamu Iri¹, Koichi Murata¹, Kohei Nishitani¹, Hiromu Ito¹, Takayuki Fujii¹, Ryu Watanabe², Takeshi Iwasaki¹, Shinichiro Nakamura¹, Shinichi Kuriyama¹, Yugo Morita¹, Yasuhiro Murakawa¹, Chikashi Terao³, Yukinori Okada⁴, Motomu Hashimoto², Shuichi Matsuda⁵, Hideki Ueno¹ and Hiroyuki Yoshitomi¹, ¹Kyoto University, Kyoto, Japan, ²Osaka Metropolitan University, Osaka, Japan, ³RIKEN, Tokyo, Japan, ⁴The University of Tokyo / Osaka University / RIKEN, Tokyo, Japan, ⁵Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, Kyoto, Kyoto, Japan
Background/Purpose: Tertiary lymphoid structures (TLSs) are organized aggregates of immune cells that are frequently observed in the target tissues of chronic diseases. In patients with…
Abstract Number: 1936 • ACR Convergence 2024
Referral and Diagnostic Delays of Patients with Chronic Inflammatory Rheumatic Diseases: A Cross-sectional Study in Eight Countries
Nelly Ziade¹, Nizar Ani², avin maroof³, ASAL ADNAN RIDHA⁴, Manal El Rakawi⁵, Chafika Haouichat⁵, Bassel Elzorkany⁶, Sherif Gamal⁷, Mariama Erraoui⁸, Manal Al-Mashaleh⁹, Fatima Alnaimat¹⁰, Basel masri¹¹, fatemah Baron¹², Lina El Kibbi¹³, Krystel Aouad¹⁴, Karen Mechleb¹⁵ and Ihsane Hmamouchi¹⁶, and ARCH ArLAR, ¹Saint-Joseph University, Beirut, Lebanon, ²Baghdad College of Medicine, Baghdad, Iraq, ³University of Kurdistan Hawler, Erbil, Iraq, ⁴Baghdad Teaching Hospital, baghdad, Iraq, ⁵Djillali Bounaama University Hospital, Algiers, Algeria, ⁶Private (BZRC), Cairo, Egypt, ⁷Cairo University, Cairo, Egypt, ⁸Souss Massa Univeristy, Rabat, Morocco, ⁹Royal Medical Services, Amman, Jordan, ¹⁰The University of Jordan, amman, Jordan, ¹¹Jordan Hospital and Medical Center, Amman, Jordan, ¹²Al-Jahra Hospital, Ministry of Health, Kuwait, Kuwait, ¹³Specialized Medical Center, Riyadh, Saudi Arabia, ¹⁴Saint George Hospital University Medical Center, Beirut, Lebanon, ¹⁵Saint Joseph University Beirut, Beirut, Lebanon, ¹⁶Rheumatology Unit, Lalla Aicha Temara Hospital, Temara, Rabat, Morocco
Background/Purpose: Patients with chronic inflammatory rheumatic diseases (CIRDs) may benefit from a critical window of opportunity for early intervention, yet referral delays remain a major…
Abstract Number: 2141 • ACR Convergence 2024
Glucocorticoid Therapy-Associated Bone Fractures Are Associated with Osteoporosis Underscreening in Patients with Rheumatoid Arthritis
Marlene Marte Furment¹ and Andras Perl², ¹SUNY Upstate Medical University, Syracuse, NY, ²SUNY, Syracuse, NY
Background/Purpose: The majority of bone loss happens within 6 months of glucocorticoid treatment. Per the 2022 American College of Rheumatology (ACR) Glucocorticoid-Induced Osteoporosis Guidelines it…
Abstract Number: 2222 • ACR Convergence 2024
Primary Lung Involvement in Early Rheumatoid Arthritis
Martí Aguilar Coll¹, Javier Narvaez-García², Alejandro Robles Pérez¹, Patricio Luburich¹, Vanesa Vicens-Zygmunt³, Gualadalupe Bermudo³, Santiago Bolivar¹, Pol Maymó³, Judith Palacios¹, Monserrat Roig Kim², Laia De Daniel², Maria Molina-Molina³ and Joan Miquel Nolla¹, ¹Bellvitge University Hospital, L'Hospitalet de Llobregat, Catalonia, Spain, ²Hospital Universitario de Bellvitge, Barcelona, Spain, ³Hospital Universitario de Bellvitge., Barcelona, Spain
Background/Purpose: Since there is broad variability within the studies investigating this issue, it is not possible nowadays to reliably establish prevalence and incidence of rheumatoid…
Abstract Number: 2238 • ACR Convergence 2024
The Effect of Inflammation on Cardiovascular Risk in Rheumatoid Arthritis Varies According to Sex and Anticitrullinated Protein Antibody Status
George Karpouzas¹, Piet Van RIel², Elena Myasoedova³, Miguel Angel Gonzalez-Gay⁴, alfonso Corrales-Martínez⁵, Solbritt Rantapaa-Dahlqvist⁶, Petros Sfikakis⁷, Patrick Dessein⁸, Linda Tsang⁹, Carol Hitchon¹⁰, Hani El Gabalawy¹¹, Virginia Pascual Ramos¹², Irazu Contreras Yanez¹³, Iris Jazmín Colunga Pedraza¹⁴, Dionicio Galarza-Delgado¹⁵, jose Ramon Azpiri-Lopez¹⁶, Anne Grete Semb¹⁷, Durga P Misra¹⁸, Patrick Durez¹⁹, Brian Bridal Logstrup²⁰, Ellen Margrethe Hauge²¹, George Kitas²² and Sarah Ormseth²³, and ATACC-RA, ¹Harbor-UCLA Medical Center, Torrance, CA, ²Radboud University Medical Center, Nijmegen, Netherlands, ³Mayo Clinic, Rochester, MN, ⁴University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, ⁵Hospital Universitario Marques de Valdecilla, Santander, Spain, ⁶Umeå University, Umeå, Sweden, ⁷Joint Academic Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens. Centre of New Biotechnologies and Precision Medicine (CNBPM), School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ⁸University of Witwatersrand, Johannesburg, South Africa, ⁹University of Witwatersrand, Johanessburg, South Africa, ¹⁰University of Mannitoba, Winnipeg, Canada, ¹¹University of Mannitoba, Winnipeg, MB, Canada, ¹²Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Federal District, Mexico, ¹³Instituto Nacional de las Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ¹⁴Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ¹⁵UANL Hospital Universitario, Monterrey, Nuevo León, Mexico, ¹⁶Division of Cardiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ¹⁷Diakonhjemmet Hospital, Oslo, Norway, ¹⁸Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ¹⁹UCLouvain, Louvain, Belgium, ²⁰University of Aarhus, Aarhus, Denmark, ²¹Aarhus Universitetshospital, Aarhus, Denmark, ²²The Dudley Group NHS Foundation Trust, Birmingham, United Kingdom, ²³The Lundquist Institute, Torrance, CA
Background/Purpose: Disease activity associated with cardiovascular (CV) risk in rheumatoid arthritis (RA). Females with RA exhibit higher disease activity than males. Yet, males with RA…
Abstract Number: 2257 • ACR Convergence 2024
Comparison of the Safety and Effectiveness of Originator Rituximab (Mabthera®) versus Biosimilar (Riximyo®) in Rheumatoid Arthritis: A Retrospective Unicentric Analysis
Barbara Bayeh¹, Fanny Neira¹, Karina Bonfiglioli¹, Nadia Aikawa², ANA PAULA ASSAD¹, Renata Miossi¹, Fernando Souza³, Carlos Emilio Insfran Echauri¹, Henrique Giardini¹, Emily Figueiredo Neves Yuki¹, Henrique Carriço Da Silva¹, Andre Franco¹, Diogo Domiciano¹, Julio Moraes⁴, Eloisa Bonfa¹, Carla Goncalves Schahin Saad³, Ana Cristina Medeiros-Ribeiro⁵ and Andrea Shimabuco³, ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ²Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil, ³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil, ⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Jundiai, Brazil, ⁵Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Jose Dos Campos, Brazil
Background/Purpose: Immunobiological drugs emerged as a revolutionary option for treating inflammatory chronic rheumatic diseases, particularly rheumatoid arthritis (RA). However, the extremely high costs associated with…
Abstract Number: 2276 • ACR Convergence 2024
Use of Methotrexate and TNF-α Inhibitors in Patients with Rheumatoid Arthritis-associated Interstitial Lung Disease: A Survey of Rheumatologists
Elizabeth Park¹, Rabia Iqbal², Elana Bernstein³ and Jon Giles⁴, ¹Columbia University Medical Center, New York, NY, ²Columbia University Irving Medical Center, Brooklyn, NY, ³Division of Rheumatology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, ⁴Cedars Sinai Medical Center, Los Angeles, CA
Background/Purpose: Interstitial lung disease (ILD) is among the most common extra-articular manifestations of RA, with symptomatic disease prevalent in approximately 10% of patients.1 Patients with…
Abstract Number: 2539 • ACR Convergence 2024
Telocytes Integrated into Mast Cells and Joint-Draining Lymphatic Vessels Potentially Regulate Lymphatic Clearance
Yue Peng¹, H. Mark Kenney², Karen Bentley¹, Lianping Xing³, Benjamin Korman⁴, Christopher Ritchlin⁵ and Edward Schwarz¹, ¹University of Rochester School of Medicine and Dentistry, Rochester, NY, ²University of Rochester School of Medicine and Dentistry, Henrietta, NY, ³University of Rochester School of Medicine and Dentistry, Webster, NY, ⁴University of Rochester, Rochester, NY, ⁵Department of Medicine, Allergy, Immunology, and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY
Background/Purpose: Rheumatoid arthritis (RA) patients and TNF-transgenic mice have lymphatic dysfunction (1). Recently, we showed mast cells involvement, as genetic ablation and drug inhibition decreased…
Abstract Number: 2636 • ACR Convergence 2024
Multi-centre Validation of a Serum Protein Biomarker Signature (RAPsA Dx), Which Discriminates Psoriatic Arthritis (PsA) from Rheumatoid Arthritis (RA)
Stephen Pennington¹, Ruoyi Zhou², Jonathan Brady², Bruna Wundervald², Andrew Parnell³, Ciarán Duffy², Robert Perryman², James Waddington⁴, Neil McHugh⁵, Deepak Jadon⁶, David Simon⁷, Filippo Fagni⁸, Georg Schett⁹, Fraser Morton¹⁰, Aurelie Najm¹⁰, Stefan Siebert¹¹, Laura Coates¹² and Oliver FitzGerald¹³, ¹UCD, Dublin, Dublin, Ireland, ²Atturos, DUBLIN, Dublin, Ireland, ³NUIM, Maynooth, Ireland, ⁴Agilent, Manchester, United Kingdom, ⁵University of Bath, Bath, United Kingdom, ⁶Cambridge University, Cambridge, United Kingdom, ⁷Charité - Universittsmedizin Berlin, Berlin, Germany, ⁸Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Deutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ⁹Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ¹⁰University of Glasgow, Glasgow, United Kingdom, ¹¹School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ¹²University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, ¹³UCD, Dublin 6, Dublin, Ireland
Background/Purpose: In a previous study, we reported the discovery and evaluation of a serum protein (22 peptide) signature (RAPsA Dx) which, when using random forest machine…
Abstract Number: 0040 • ACR Convergence 2024
Targeting Complement Factor B (CFB) via a Novel siRNA Therapy (AZD6912) to Treat Inflammatory Arthritis
Gary Sims¹, Mia Collins², Natalie Pursell³, Teneema Kuriakose¹, Fanyi Jiang⁴, Kristi Moore⁵, Lucie Bertrand⁵, Melissa Lasaro⁵, Jessica Neisen⁶, Scott Manetz⁷, Gabriel Wong⁸, Patrick Riley⁵, Iain McInnes⁹, Kyriakos Konstantinidis¹⁰ and David Close⁸, ¹Immunology Biosciences, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ²Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ³Dicerna, Lexington, ⁴Translation and Experimental Medicine, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ⁵Alexion, AstraZeneca Rare Disease, New Haven, CT, ⁶Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ⁷Clinical Pharmacology and Safety Science, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁸Early Clinical Development, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ⁹University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, ¹⁰Projects, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom
Background/Purpose: New precision medicine guided therapies targeting alternate disease driving processes are required to improve clinical outcomes in RA. The complement pathway has long been…
Abstract Number: 0057 • ACR Convergence 2024
Flow Cytometry of Cells Within Induced Sputum from Individuals At-Risk for RA Reveals Relative Expansion of Small Macrophages
Hideto Takada¹, Brian Hattel², Marie Feser³, LauraKay Moss², Yuko Okamoto⁴, Mark Gillespie⁵, Adam Savage⁵, Troy Torgerson⁶, V. Michael Holers⁷, Kevin Deane⁸ and Kristen Demoruelle⁹, ¹Tokyo Women's Medical University, Denver, CO, ²University of Colorado Anschutz Medical Campus, Denver, CO, ³Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁴Tokyo Women's Medical University Division of Rheumatology, Shinjyuku-ku, Tokyo, Japan, ⁵Allen Institute for Immunology, Seattle, WA, ⁶Allen Institute for Immunology, Enumclaw, WA, ⁷University of Colorado, Denver, CO, ⁸University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ⁹University of Colorado Anschutz Medical Campus, Golden, CO
Background/Purpose: Serum elevations of ACPA in the absence of inflammatory arthritis is a well-established risk factor for the future development of clinical RA. The lung…
Abstract Number: 0140 • ACR Convergence 2024
Estimation of 10-year Cardiovascular (CV) Risk and Traditional CV Risk Factors Distribution in Patients with Rheumatoid Arthritis from Three Italian Macro-areas
Fabiola Atzeni¹, Fabio Cacciapaglia², Elena Bartoloni Bocci³, Matteo Piga⁴, Garifallia Sakellariou⁵, Ombretta Viapiana⁶, Alessandro Giollo⁷, SIMONE PARISI⁸, Maria Sole Chimenti⁹, Ennio Giulio Favalli¹⁰, Addolorata Corrado¹¹, Eleonora Celletti¹², Ivan Giovannini¹³, Serena Guiducci¹⁴, Elisa Gremese¹⁵, Andreina Manfredi¹⁶, Francesca Romana Spinelli¹⁷ and Gian Luca Erre¹⁸, and "Cardiovascular Obesity and Rheumatic DISeaases" Study Group of the Italian Society of Rheumatology, ¹University of Messina, Italy, Messina, Italy, ²Rheumatology Unit DiMePRe-J, University and AOU Policlinico of Bari, Italy, Bari, Italy, ³Rheumatology Unit. Department of Medicine, Perugia, Perugia, Italy, ⁴Rheumatology Unit - Department of Medical Sciences and Public Health, University of Cagliari, Monserrato, Italy, ⁵Department of Internal Medicine and Medical Therapy, University of Pavia, and Istituti Clinici Scientifici Maugeri IRCCS Pavia,, Pavia, Italy, ⁶Rheumatology Unit, University of Verona, Verona, Italy, ⁷Azienda Ospedale Università Padova, Padova, Padua, Italy, ⁸Rheumatology Unit, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, TURIN, Italy, ⁹Rheumatology, Allergology and Clinical Immunology, University of Rome Tor Vergata, Roma, Italy, ¹⁰ASST Gaetano Pini-CTO, Milan, Lombardia, Italy, ¹¹Rheumatology Unit, University of Foggia, Foggia, Italy, ¹²Medical Clinic, SS. Annunziata Hospital of Chieti, Department of Medicine and Science of Aging, G. D'Annunzio University of Chieti-Pescara, Chieti, Italy, ¹³Azienda Sanitaria Universitaria Friuli Centrale, Udine, Udine, Italy, ¹⁴University of Florence, Pistoia, Italy, ¹⁵Catholic University of the Sacred Heart, Rome, Rome, Italy, ¹⁶University of Modena and Reggio Emilia, Modena, ¹⁷Sapienza University of Rome, Rome - Italy, Roma, Rome, Italy, ¹⁸Rheumatology Unit - University of Sassari, Sassari, Italy
Background/Purpose: Geographic origins can significantly impact people’s health, particularly in Italy, where regional health disparities are among the most pronounced [1]. Rheumatoid arthritis (RA) is…
Abstract Number: 0222 • ACR Convergence 2024
The Prediction of Response to Advanced Therapies on a Joint Level in Rheumatoid Arthritis: The Interpretation of Tenderness and Doppler Ultrasound
Ricardo Sabido-Sauri¹, Seyyid Bilal Acikgoz², Ummugulsum Gazel¹, Ozun Bayindir Tsechelidis³, Sylvia Sangwa⁴, Catherine Ivory⁵, Elliot Hepworth¹ and Sibel Aydin⁶, ¹University of Ottawa, Ottawa, ON, Canada, ²University of Ottawa, Rheumatology, Ottawa, ON, Canada, ³Ottawa University, Ottawa, ON, Canada, ⁴The Ottawa Hospital Research Institute, Ottawa, Canada, ⁵The Ottawa Hospital, Ottawa, ON, Canada, ⁶University of Ottawa - Ottawa, Ottawa, ON, Canada
Background/Purpose: There are discrepancies between physical examination and Ultrasound (US) in detecting inflammation in Rheumatoid Arthritis (RA). In this study, we aimed to understand, according…
Abstract Number: 0364 • ACR Convergence 2024
Exploring 24-Hour Temporal Trends in Symptoms and Treatment of Rheumatic Disease Through Google Search Trends
Insa Mannstadt¹, J. Alex B. Gibbons² and Bella Mehta³, ¹Columbia University VP&S, New York, NY, ²Columbia University Vagelos College of Physicians & Surgeons, New York, NY, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Symptoms of rheumatic diseases such as joint stiffness and pain are known to peak in the early morning hours. In the digital age, tracking…
Abstract Number: 0461 • ACR Convergence 2024
Complete Description of the Three Pathways of the Complement System in a Series of 430 Patients with Rheumatoid Arthritis
ivan Ferraz-Amaro¹, Maria Garcia-Gonzalez², Fuensanta Gomez-Bernal³, Juan Carlos Quevedo-Abeledo⁴ and Miguel Angel Gonzalez-Gay⁵, ¹Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, ²Hospital Universitario de Canarias, SC Tenerife, Canarias, Spain, ³Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, ⁴Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de GC, Canarias, Spain, ⁵University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain
Background/Purpose: The complement (C) system has been implicated in the etiopathogenesis of rheumatoid arthritis (RA). We aimed to examine the correlation between an in-depth evaluation…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].